Skip to content

Speech Therapy of Parkinson's Disease Patients by Interpreting Texts

Speech Therapy of Parkinson's Disease Patients by Interpreting Texts - STOP-IT

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00006333
Enrollment
30
Registered
2014-07-22
Start date
2013-09-30
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

G20

Interventions

Group 1: Speech and voice treatment focussing respiration, articulation and phonation, 8 training sessions (45 min) over a period of 2 weeks Group 2: Speech and voice treatment focussing fundamentals

Sponsors

Universitätsklinikum Jena
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 85 Years

Inclusion criteria

Inclusion criteria: Parkinson's disease (Brain Bank criteria, Hoehn & Yahr stage 2 - 4) with hypophonic dysarthria

Exclusion criteria

Exclusion criteria: Presence of dementia or atypical Parkinson's disease, ongoing speech therapy during the trial, text blindness

Design outcomes

Primary

MeasureTime frame
Changes in intelligibility on the level of words, sentencesand texts as well as in spontaneous speech one day after the last training session and 3 months later (assessment by blinded listeners)

Secondary

MeasureTime frame
Changes in self perception and perception by others according to the voice handicap index (VHI), communication-related quality of life (PDQ-39), changes in acoustic parameters one day after the last training session as well as 3 months later

Countries

Germany

Contacts

Public ContactBeate;Sara Redecker;Neuhauser

Institut für Germanistische Sprachwissenschaft, Friedrich-Schiller-Universität Jena;Institut für Germanistische Sprachwissenschaft, Friedrich-Schiller-Universität Jena

beate.redecker@uni-jena.de;sara.neuhauser@uni-jena.de+49 3641 944337;+49 3641 944028

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026